secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2026-07-22T12:56:58+00:00
Accession:  0001193125-26-311402
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen to acquire BioLife Solutions for ~$1.5B; reports preliminary Q2 revenue growth of ~12%
--------------------------------------------------------------------------------

- Repligen to acquire BioLife for ~$1.5B; per share consideration $31.00 ($11.25 cash + 0.1442 RGEN shares).
- Deal expected to close Q4 2026; boards unanimously approved; subject to BLFS stockholder approval and HSR clearance.
- Expected to be accretive: at least $0.05 adjusted EPS in year one, at least $0.25 in year two.
- Repligen preliminary Q2 revenue growth ~12% (13% organic); BioLife preliminary Q2 revenue growth ~21% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/0001193125-26-311402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312526311402/d141685d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-311402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer